Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
NCT07809724
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Beijing, Beijing Municipality, China
View Trial DetailsNCT Number: NCT07032337
Newly diagnosed NMOSD patients
Looking for future studies?
Notify MeAll sexes
Observational
From 2011 to 2022, newly diagnosed NMOSD patients who had not previously claimed NMOSD. Exclusion criteria were history of cancer or had used ISTs (excluding steroids) prior to the NMOSD diagnosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Relapses were identified when patients were treated with one of the following interventions: intravenous steroids, immunoglobulin therapy, or plasma exchange.
Time frame: 6 months after start of ISTs
Incidence of serious infection, fracture, cancer, myocardial infarction, stroke, depression, anxiety, dementia, and Parkinson's disease which defined as presence of ICD-10 codes.
Samsung Medical Center
Other
Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder: A Target Trial Emulation Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07809724
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Beijing, Beijing Municipality, China
View Trial DetailsNCT07526493
Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Disease (MOGAD), Autoimmune Diseases
Wuhan, Hubei, China
View Trial DetailsNCT07085676
Antiphospholipid Antibody Syndrome, Antiphospholipid Syndrome
Jerusalem, Israel
View Trial DetailsNCT06312644
Anemia, Anemia, Hemolytic
Boston, Massachusetts, United States
View Trial Details